See more : Meier Tobler Group AG (MTG.SW) Income Statement Analysis – Financial Results
Complete financial analysis of Embecta Corp. (EMBC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Embecta Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Ursus S.A. (URS.WA) Income Statement Analysis – Financial Results
- Tai Hing Group Holdings Limited (6811.HK) Income Statement Analysis – Financial Results
- OYAK Çimento Fabrikalari A.S. (OYAKC.IS) Income Statement Analysis – Financial Results
- Adecoagro S.A. (0DWL.L) Income Statement Analysis – Financial Results
- Sunty Development Co., LTD (3266.TW) Income Statement Analysis – Financial Results
Embecta Corp. (EMBC)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.embecta.com
About Embecta Corp.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 1.12B | 1.12B | 1.13B | 1.17B | 1.09B | 1.11B |
| Cost of Revenue | 387.90M | 370.90M | 354.60M | 365.00M | 322.90M | 323.00M |
| Gross Profit | 735.20M | 749.90M | 774.90M | 800.00M | 762.60M | 786.00M |
| Gross Profit Ratio | 65.46% | 66.91% | 68.61% | 68.67% | 70.25% | 70.87% |
| Research & Development | 78.80M | 85.20M | 66.90M | 63.00M | 61.40M | 62.00M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | -300.00K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 240.00M | 215.00M | 222.00M |
| SG&A | 365.10M | 341.30M | 294.80M | 240.00M | 214.70M | 222.00M |
| Other Expenses | 124.50M | 101.90M | 44.70M | 5.00M | -700.00K | -2.00M |
| Operating Expenses | 568.40M | 528.40M | 406.40M | 308.00M | 276.10M | 284.00M |
| Cost & Expenses | 956.30M | 899.30M | 761.00M | 673.00M | 599.00M | 607.00M |
| Interest Income | 0.00 | 0.00 | 46.20M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 112.30M | 107.00M | 46.20M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 36.20M | 32.60M | 31.70M | 38.00M | 38.00M | 36.00M |
| EBITDA | 199.00M | 245.40M | 400.20M | 530.00M | 524.00M | 538.00M |
| EBITDA Ratio | 17.72% | 21.90% | 34.83% | 45.49% | 48.28% | 48.51% |
| Operating Income | 166.80M | 221.50M | 309.60M | 492.00M | 486.50M | 502.00M |
| Operating Income Ratio | 14.85% | 19.76% | 27.41% | 42.23% | 44.82% | 45.27% |
| Total Other Income/Expenses | -122.60M | -115.80M | -53.00M | 3.00M | -700.00K | -2.00M |
| Income Before Tax | 44.20M | 105.70M | 256.60M | 495.00M | 485.80M | 500.00M |
| Income Before Tax Ratio | 3.94% | 9.43% | 22.72% | 42.49% | 44.75% | 45.09% |
| Income Tax Expense | -34.10M | 35.30M | 33.00M | 80.00M | 58.20M | 68.00M |
| Net Income | 78.30M | 70.40M | 223.60M | 414.80M | 427.60M | 432.00M |
| Net Income Ratio | 6.97% | 6.28% | 19.80% | 35.61% | 39.39% | 38.95% |
| EPS | 1.36 | 1.23 | 3.92 | 7.31 | 7.50 | 7.58 |
| EPS Diluted | 1.34 | 1.22 | 3.92 | 7.31 | 7.50 | 7.58 |
| Weighted Avg Shares Out | 0.00 | 57.24M | 57.06M | 56.80M | 57.00M | 57.00M |
| Weighted Avg Shares Out (Dil) | 0.00 | 57.76M | 57.06M | 56.80M | 57.00M | 57.00M |
New Strong Buy Stocks for March 30th
3 Medical Services Stocks to Buy Amid Industry Challenges
New Strong Buy Stocks for February 24th
Best Value Stocks to Buy for February 24th
New Strong Buy Stocks for February 21st
Why Embecta Stock Popped by Nearly 13% Today
Embecta Corp. (EMBC) Q1 2023 Earnings Call Transcript
Dividend Income Update: January 2023
embecta to Participate in Upcoming Investor Conferences
embecta to Report Fiscal First Quarter 2023 Financial Results
Source: https://incomestatements.info
Category: Stock Reports